 At least 3 weeks must have elapsed since completion of last chemotherapy and 4 weeks since last radiation, prior to first dose of Xofigo. Patients are not permitted to receive any form of maintenance chemotherapy or biologictargeted anticancer therapy while being treated on this study Life expectancy of at least 12 weeks 3 months. Patients with treated brain metastases are allowed, but must have brain imaging showing evidence of stability since most recent treatment for brain mets, prior to first dose of Xofigo. For patients with brain metastases only, brain imaging is required. Patients who do not have brain metastases or symptoms of potential brain metastases are not required to have baseline brain imaging, but this must be confirmed in writing Eastern Cooperative Oncology Group ECOG Performance Status of 0 - 1. Required entry laboratory parameters within 14 days of study entry: White Blood Cell Count WBC 3,000mm3; Absolute Neutrophil Count ANC 1,500mm3; Platelet PLT count 100,000mm3; Hemoglobin Hgb 9gdl, Total bilirubin level 1.5 x institutional upper limit of normal ULN; Aspartate aminotransferase AST and alanine aminotransferase ALT 2.5 x ULN ; Creatinine 1.5 x ULN; Albumin 2.5 gdL. 